In two clinical trials in China, it was described that patients with CRC had lower expression of IL-9 in plasma and CRC tumor tissue, and the expression level was correlated with the tumor stage: the more advanced the tumor stage, the lower the IL-9 serum level. The gene discussed is IL9; the disease is neoplasm.